Metabolic medicines
Mazdutide
A dual glucagon/GLP-1 receptor agonist with phase III weight-change data in Chinese adults with obesity.
Human clinical research
Also known as: IBI362
Practical use
Applying the explained evidence
- Where it fits
- A dual glucagon/GLP-1 receptor agonist with phase III weight-change data in Chinese adults with obesity.
- Put the information into practice
- Interpret the treatment, population and background support together. This is not a head-to-head ranking against every other metabolic medicine.
- The outcome being treated
- Identify whether the evidence concerns a diagnosed condition, body weight, appetite or a laboratory marker. Check which outcomes were measured and over what follow-up before transferring a finding to another goal.
- Keep this limit in view
- Results concern this population and follow-up period. A weight endpoint does not establish a cardiovascular-event or longevity benefit.
Overview
Mazdutide combines glucagon- and GLP-1-receptor agonism. GLORY-2 compared it with placebo alongside reduced-calorie eating and physical activity.
Risks and limitations
GLORY-2 reported vomiting in 53.1% versus 1.3%, nausea in 46.9% versus 3.2%, and diarrhea in 39.4% versus 6.5%. Most were mild or moderate; adverse events led to treatment discontinuation in 2.9% versus 0%.
How to read this
Interpret the treatment, population and background support together. This is not a head-to-head ranking against every other metabolic medicine.
Research explained
GLORY-2: 60-week phase III trial
Who was studied
461 treated participants at 27 hospitals in China; BMI at least 30. Mean age 33.9; 16.1% had type 2 diabetes.
- Mazdutide mean weight change
- -16.65 %
- Placebo mean weight change
- -1.5 %
What was found
Mean weight change was −16.65% with mazdutide versus −1.50% with placebo. The estimated difference was −15.15 percentage points (95% CI −17.22 to −13.09).
What it cannot establish
Results concern this population and follow-up period. A weight endpoint does not establish a cardiovascular-event or longevity benefit.
Read the original studySources
GLORY-2: 60-week phase III trial
Sources checked 2026-09-28.
General education; not a personal treatment plan.